April round-up of pharma/biotech M&A activity

3 May 2016
mergers-acquisitions-big

The collapse of the $160 billion mega merger between US pharma giant Pfizer (NYSE: PFE) and Ireland-incorporated Allergan (NYSE: AGN) set the tone for a quiet month for pharmaceutical collaborations and acquisitions, though things livened up as April ended.

Signs of increased activities in recent days have included US biopharma major AbbVie (NYSE: ABBV) acquiring oncology firm Stemcentrx, and the upping of interest from several companies in USA-based Medivation (Nasdaq: MDVN), with French pharma giant Sanofi (Euronext: SAN) having its $9.3 billion takeover bid rejected, though tals are expected to continue.

Biggest deal:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical